These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22024105)

  • 1. Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials.
    Dixon DO; Weiss S; Cahill K; Fox L; Love J; McNamara J; Soto-Torres LE
    Clin Trials; 2011 Dec; 8(6):727-35. PubMed ID: 22024105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experiences and challenges in data monitoring for clinical trials within an international tropical disease research network.
    Chen-Mok M; VanRaden MJ; Higgs ES; Dominik R
    Clin Trials; 2006; 3(5):469-77. PubMed ID: 17060220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the data safety and monitoring board in an international trial.
    NIMH Collaborative HIV/STD Prevention Trial
    AIDS; 2007 Apr; 21 Suppl 2():S99-102. PubMed ID: 17413269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data safety and monitoring boards for African clinical trials.
    Lang T; Chilengi R; Noor RA; Ogutu B; Todd JE; Kilama WL; Targett GA
    Trans R Soc Trop Med Hyg; 2008 Dec; 102(12):1189-94. PubMed ID: 18644610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
    DeMets DL; Fleming TR; Whitley RJ; Childress JF; Ellenberg SS; Foulkes M; Mayer KH; O'Fallon J; Pollard RB; Rahal JJ
    Control Clin Trials; 1995 Dec; 16(6):408-21. PubMed ID: 8720018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing training for Data Safety Monitoring Board members: A National Institute of Allergy and Infectious Diseases case study.
    Zuckerman J; van der Schalie B; Cahill K
    Clin Trials; 2015 Dec; 12(6):688-91. PubMed ID: 26152835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sharing interim trial results by the Data Safety Monitoring Board with those responsible for the trial's conduct and progress: a narrative review.
    Borg Debono V; Mbuagbaw L; Thabane L
    Trials; 2017 Mar; 18(1):120. PubMed ID: 28279205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Data safety monitoring boards: legal and ethical considerations for research accountability.
    Tereskerz PM
    Account Res; 2010 Jan; 17(1):30-50. PubMed ID: 20094929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [DSMB. 2. The importance of an efficient DSMB: some examples of high-risk clinical trials].
    Brun-Buisson C
    Med Sci (Paris); 2005 Feb; 21(2):187-9. PubMed ID: 15691491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What information should a sponsor of a randomized trial receive during its conduct?
    Anand SS; Wittes J; Yusuf S
    Clin Trials; 2011 Dec; 8(6):716-9. PubMed ID: 22024103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring participant safety in phase I and II interventional trials: options and controversies.
    Hibberd PL; Weiner DL
    J Investig Med; 2004 Nov; 52(7):446-52. PubMed ID: 15651260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.
    Wittes J; Barrett-Connor E; Braunwald E; Chesney M; Cohen HJ; Demets D; Dunn L; Dwyer J; Heaney RP; Vogel V; Walters L; Yusuf S
    Clin Trials; 2007; 4(3):218-34. PubMed ID: 17715247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Securely sharing DSMB reports to speed decision making from multiple, concurrent, independent studies of similar treatments in COVID-19.
    Dilts NA; Harrell FE; Lindsell CJ; Nwosu S; Stewart TG; Shotwell MS; Pulley JM; Edwards TL; Serdoz ES; Benhoff K; Bernard GR
    J Clin Transl Sci; 2022; 6(1):e49. PubMed ID: 35656334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Building a more connected DSMB: better integrating ethics review and safety monitoring.
    Eckstein L
    Account Res; 2015; 22(2):81-105. PubMed ID: 25397600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [DSMB. 1. What role, what responsibilities?].
    Brun-Buisson C
    Med Sci (Paris); 2005 Jan; 21(1):78-82. PubMed ID: 15639025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reporting of data monitoring boards in publications of randomized clinical trials is often deficient: ACTTION systematic review.
    Gewandter JS; Kitt RA; Hunsinger MR; Poku J; Lozano J; Chaudari J; Evans S; Gross RA; McDermott MP; Rowbotham MC; Turk DC; Dworkin RH
    J Clin Epidemiol; 2017 Mar; 83():101-107. PubMed ID: 28126598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent data and safety monitoring in psychiatric intervention research.
    Leon AC
    J Clin Psychiatry; 2012 Feb; 73(2):e257-63. PubMed ID: 22401486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.